deltatrials
Completed PHASE2 NCT02153918

Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy

A Phase II Study of Neoadjuvant rFowlpox-PSA (L155)-TRICOM (Prostvac-F/TRICOM) in Combination With rVaccinia-PSA (L155)-TRICOM (Prostvac-V/TRICOM) in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy

Sponsor: National Cancer Institute (NCI)

Conditions Neoplasms, Prostate Prostate Cancer Prostatic Neoplasms
Interventions PROSTVAC-F/TRICOM PROSTVAC-V/TRICOM
Updated 8 times since 2017 Last updated: Sep 12, 2018 Started: May 31, 2014 Primary completion: Jul 28, 2017 Completion: Jan 16, 2018

Listed as NCT02153918, this PHASE2 trial focuses on Neoplasms, Prostate and Prostate Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 8 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Nov 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jun 2018 — Nov 2018 [monthly]

    Completed PHASE2

▶ Show 3 earlier versions

  1. Feb 2018 — Jun 2018 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Feb 2017 — Feb 2018 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States